

ENANTA Pharmaceuticals, Inc.


500 Arsenal Street
Watertown, Massachusetts
02472

Tel: 617.607.0800
Fax: 617.607.0530
www.enanta.com

FOR IMMEDIATE RELEASE

CONTACT:

Susan Burke, Account Executive
Ronald Trahan Associates, Inc.
508-647-9782, ext. 20



**Enanta Pharmaceuticals appoints
Dr. Andrew J. Sonderfan as Director of
Toxicology and Safety Pharmacology**

CAMBRIDGE, Mass., Aug 15, 2001 -- Enanta Pharmaceuticals Inc., an emerging biopharmaceutical company, announced today the appointment of Andrew Sonderfan, Ph.D., DABT, as Director of Toxicology and Safety Pharmacology.

Prior to joining Enanta Pharmaceuticals, Dr. Sonderfan was Director of Toxicology and Product Safety at Shire Pharmaceutical Development, Inc. (formerly BioChem Pharma). From 1998-2000, Dr. Sonderfan held the position of Director of Preclinical Development at MacroChem Corporation; and from 1994-1998, he held several positions at Procept Inc., most recently as Director of Preclinical Safety Evaluation. Dr. Sonderfan earned a doctorate in toxicology from the University of Kansas Medical Center after receiving his bachelor's degree in toxicology from the Philadelphia College of Pharmacy and Science. He is certified as a Diplomate of the American Board of Toxicology (DABT), and is a member of the American Association for the Advancement of Science (AAAS).

"Dr. Sonderfan possesses vast experience in drug evaluation and toxicology, and has authored or co-authored numerous peer-reviewed papers published in such scientific journals as Archives of Biochemistry and Biophysics, the Journal of Pharmacology, and the Journal of Infectious Diseases. We are fortunate to have him join our management team at this particular time, as we have moved several of our drug-discovery programs into preclinical development this year," said Dr. Spiros Jamas, Enanta's president and chief executive officer.

Enanta Pharmaceuticals, founded in 1998, has raised \$25 million to date in private financing. Investors include: Oxford Bioscience Partners (lead investor), TVM - Techno Venture Management, Advent International Corporation, Lancet Capital and others.

Headquartered in Cambridge, Mass., Enanta Pharmaceuticals is creating its patented Morphed Chemical Entity (MCE™) libraries by transforming existing drugs, natural products and peptides into novel small-molecule drugs. The Company's initial focus is on MCEs derived from existing drugs that address significant unmet medical needs: (a) new generation macrolide antibiotics to overcome bacterial resistance; and (b) anti-

inflammatory drugs for a variety of indications, including asthma, psoriasis and inflammatory bowel diseases. Enanta is also using its proprietary Peptide Morphing™ capability to create improved antiviral drugs for HCV, HIV and HPV.

#####